325,000 Shares in CAMP4 Therapeutics Corporation $CAMP Purchased by EcoR1 Capital LLC

EcoR1 Capital LLC acquired a new stake in shares of CAMP4 Therapeutics Corporation (NASDAQ:CAMP) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm acquired 325,000 shares of the Wireless communications provider’s stock, valued at approximately $1,992,000. CAMP4 Therapeutics makes up 0.1% of EcoR1 Capital LLC’s investment portfolio, making the stock its 27th biggest holding.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the company. Bridgeway Capital Management LLC bought a new stake in shares of CAMP4 Therapeutics during the second quarter valued at approximately $36,000. China Universal Asset Management Co. Ltd. purchased a new stake in CAMP4 Therapeutics during the 4th quarter valued at $61,000. Jefferies Financial Group Inc. bought a new stake in shares of CAMP4 Therapeutics in the 4th quarter worth $70,000. Bank of America Corp DE purchased a new position in CAMP4 Therapeutics in the 4th quarter worth about $86,000. Finally, Goldman Sachs Group Inc. purchased a new position in shares of CAMP4 Therapeutics during the fourth quarter valued at approximately $115,000.

CAMP4 Therapeutics Stock Performance

Shares of CAMP4 Therapeutics stock opened at $4.14 on Thursday. CAMP4 Therapeutics Corporation has a fifty-two week low of $1.30 and a fifty-two week high of $7.75. The company has a market capitalization of $214.97 million, a P/E ratio of -1.75 and a beta of 0.08. The company has a fifty day moving average of $4.34 and a 200 day moving average of $4.70.

CAMP4 Therapeutics (NASDAQ:CAMP) last announced its quarterly earnings data on Thursday, May 7th. The Wireless communications provider reported ($0.32) EPS for the quarter, missing the consensus estimate of ($0.21) by ($0.11). The business had revenue of $1.29 million during the quarter. CAMP4 Therapeutics had a negative net margin of 2,193.72% and a negative return on equity of 194.74%. Analysts forecast that CAMP4 Therapeutics Corporation will post -0.82 EPS for the current year.

Wall Street Analysts Forecast Growth

CAMP has been the subject of a number of research analyst reports. Weiss Ratings downgraded shares of CAMP4 Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, May 21st. Leerink Partners lifted their price objective on CAMP4 Therapeutics from $8.00 to $9.00 and gave the stock an “outperform” rating in a report on Thursday, April 2nd. JPMorgan Chase & Co. upgraded CAMP4 Therapeutics from a “neutral” rating to an “overweight” rating and upped their price objective for the company from $5.00 to $9.00 in a research report on Tuesday. Rodman & Renshaw started coverage on CAMP4 Therapeutics in a report on Tuesday, April 14th. They issued a “buy” rating and a $7.00 target price on the stock. Finally, Chardan Capital set a $6.50 target price on CAMP4 Therapeutics and gave the stock a “buy” rating in a research report on Wednesday, June 10th. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $8.36.

CAMP4 Therapeutics Profile

CalAmp Corp., a connected intelligence company, provides leverages a data-driven solutions ecosystem to people and organizations in the United States, Europe, the Middle East, Africa, Latin America, the Asia-Pacific, and internationally. The company operates in two segments, Software & Subscription Services and Telematics Products. It provides CalAmp Telematics Cloud platform, such as cloud-based application enablement and telematics service platforms that facilitate integration of its own applications, as well as those of third parties, through open application programming interfaces; and software as a service application, as well as provides tracking and monitoring services within fleet management, supply chain integrity, and international vehicle location.